◎ Sugi Atlas

Atlas / Disease / Obsessive-compulsive personality disorder

Obsessive-compulsive personality disorder

disease
On this page

Also known as OCD

Summary

Obsessive-compulsive personality disorder (MONDO:0001158) is a disease and 51 clinical trials. Top therapeutic interventions include fluvoxamine, pyridoxine, and escitalopram. A subtype of personality disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 51

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameobsessive-compulsive personality disorder
Mondo IDMONDO:0001158
MeSHD003193
DOIDDOID:10932
ICD-10-CMF60.5
ICD-111570535959
NCITC92638
SNOMED CT1376001
UMLSC0009595
MedGen40432
Is cancer (heuristic)no

Also known as: OCD

Disease family

This is a subtype of personality disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › personality disorder › obsessive-compulsive personality disorder

Related subtypes (9): schizotypal personality disorder, borderline personality disorder, dependent personality disorder, schizoid personality disorder, paranoid personality disorder, antisocial personality disorder, avoidant personality disorder, narcissistic personality disorder, histrionic personality disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 51.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified41
PHASE43
PHASE23
EARLY_PHASE12
PHASE1/PHASE21
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00708396PHASE4UNKNOWNTolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study
NCT04963257PHASE4UNKNOWNSertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder
NCT06231095PHASE4COMPLETEDDoes TMS Affect Neuroplasticity? The Role of Brain-derived Neurotrophic Factor and Neuronal Cell Adhesion Molecules - an Intensive Clinical Protocol Among Patients With Obsessive-compulsive Disorders
NCT05624528PHASE2ACTIVE_NOT_RECRUITINGA Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
NCT00215137PHASE2COMPLETEDPilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder
NCT00523718PHASE2COMPLETEDRiluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
NCT02797808PHASE1/PHASE2COMPLETEDEffects of Sertraline on Brain Connectivity in Adolescents With OCD
NCT06442423PHASE1RECRUITINGOpen-Label Psilocybin Study in Transdiagnostic Population
NCT06282146EARLY_PHASE1ACTIVE_NOT_RECRUITINGTesting a Transdiagnostic TMS Treatment Target
NCT06720090EARLY_PHASE1RECRUITINGLight Therapy for Obsessive-compulsive Disorder (OCD)
NCT03313622Not specifiedNOT_YET_RECRUITINGLocating Biomarkers in OCD Through Behavioral Tasks
NCT03459456Not specifiedACTIVE_NOT_RECRUITINGMeasuring Automated Behavioral Observations & Vocal Expressions (ABOVE)
NCT03511534Not specifiedACTIVE_NOT_RECRUITINGOpen/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder
NCT04982757Not specifiedRECRUITINGAccelerated TMS for Depression and OCD
NCT05359562Not specifiedRECRUITINGHow Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
NCT05580614Not specifiedRECRUITINGPaired tVNS With ERP in OCD
NCT05712057Not specifiedRECRUITINGNeurostimulation Versus Therapy for Problems With Emotions
NCT05843604Not specifiedRECRUITINGCerebral and Cognitive Markers of Treatment Resistance in Obsessive Compulsive Disorder
NCT05881356Not specifiedRECRUITINGDiscovering Factors in the Clinical Study Journey of Patients With OCD
NCT05994053Not specifiedRECRUITINGNeuromodulation for a Novel OCD Biomarker and Treatment
NCT06050369Not specifiedRECRUITINGObjective Characterizatoion of Repetitive Behaviors
NCT06347978Not specifiedRECRUITINGPersonalized DBS for OCD Guided by Stereoencephalography Mapping
NCT06624137Not specifiedRECRUITINGComputer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
NCT06731426Not specifiedRECRUITINGMulti-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion
NCT06913738Not specifiedRECRUITINGEvaluation of a Dimensional Adaptation of Good Psychiatric Management (GPM-extended) for the Treatment of Borderline Personality Disorder
NCT06934525Not specifiedRECRUITINGImplementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
NCT06978452Not specifiedRECRUITINGBehavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories
NCT06997549Not specifiedRECRUITINGRetrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
NCT00399022Not specifiedWITHDRAWNTreatment With Duloxetine for OCD Patients
NCT01298622Not specifiedUNKNOWNThe Imaging Genetic Study of the Core Family of Obsessive-compulsive Disorder (OCD) Patient
NCT01723033Not specifiedUNKNOWNDifferences in Cognitive Performance and Brain Activity Between Patients With PTSD and OCD
NCT01833442Not specifiedCOMPLETEDRandomized Controlled Meditation Trial for Treating OCD
NCT01936051Not specifiedCOMPLETEDModeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients
NCT02500888Not specifiedUNKNOWNEvaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder
NCT02866422Not specifiedCOMPLETEDDevelopment of an Instrument That Monitors Behaviors Associated With OCD
NCT03404609Not specifiedCOMPLETEDRapid Non-Invasive Brain Stimulation for OCD (oTMS)
NCT03528109Not specifiedUNKNOWNImproving Access to Child Anxiety Treatment
NCT03682913Not specifiedUNKNOWNPersonalized Inhibitory Control Training for Compulsive Behavior Change
NCT03754647Not specifiedUNKNOWNEffect of Vitamin C Upon SSRI-treated OCD Patients
NCT03833531Not specifiedCOMPLETEDEffectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and CPD

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
FLUVOXAMINE43
PYRIDOXINE43
ESCITALOPRAM42
RILUZOLE41
SERTRALINE41
TOLCAPONE41
CHEMBL178836101

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 22

This page pulls from 22 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardoidefogenccgwasgwas_studyhgncicd10cmicd11medgenmeshmimmondomondochildmondoparentncitorphanetsctidumls